Vimarsana
Biggest News Aggregation in the World

Slate Development News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Slate Development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Slate Development Today - Breaking & Trending Today

No timeline for construction on Regency Inn housing project - Vimarsana News

No timeline for construction on Regency Inn housing project

Regency Inn, an old motel property located at 2701 N. O. Henry Boulevard in Greensboro, has been sitting vacant for roughly a year and a half, by Greensboro city manager

Two truths and a lie – addressing Africa's race for inward investment - Vimarsana News

Two truths and a lie – addressing Africa's race for inward investment

The point of two truths and a lie is they are all believable except not all accurate. That attracting FDI is necessary for Africa’s growth equation is true.

Creative Europe MEDIA Monthly Round-up - November | The Irish Film & Television Network - Vimarsana News

Creative Europe MEDIA Monthly Round-up - November | The Irish Film & Television Network

The latest news stories from the Irish Film & Television Network, on production, training opportunities, casting and much more.

Source: iftn.ie
Accelerated Approvals Withdrawn for Ibrutinib in Mantle Cell Lymphoma, Marginal Zone Lymphoma - Vimarsana News

Accelerated Approvals Withdrawn for Ibrutinib in Mantle Cell Lymphoma, Marginal Zone Lymphoma

Accelerated approvals for ibrutinib (Imbruvica) for patients with mantle cell lymphoma and with marginal zone lymphoma voluntarily withdrawn based on data that were insufficient to support conversion to full approval.

Johnson & Johnson : New Results from the Phase 3 GLOW Study of Fixed-Duration Treatment with IMBRUVICA® (ibrutinib) Plus Venetoclax Demonstrate Robust Efficacy and Sustained Response in Older, Unfit Patients with Previously Untreated Chronic Lymphocytic Leukemia - Vimarsana News

Johnson & Johnson : New Results from the Phase 3 GLOW Study of Fixed-Duration Treatment with IMBRUVICA® (ibrutinib) Plus Venetoclax Demonstrate Robust Efficacy and Sustained Response in Older, Unfit Patients with Previously Untreated Chronic Lymphocytic Leukemia

NEW ORLEANS, December 10, 2022 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new four-year follow-up results from the Phase 3 GLOW study , which... | December 10, 2022